Main Industry
Biotechnology
Main Product/Service
i-OBM develops innovative drug formulations using existing active ingredients, focusing on enhancing efficacy, reducing side effects, and extending drug half-life through advanced delivery systems. Their technologies include chelating complex micelles, tr
Founded Year
2011
Unified Business No.
29184891
Status
Active
Number of Employees
0
Total Paid-in
Capital
665,890,000 (NT$)
Location of Company
Taiwan
, Tainan City
Exit Status
Emerging Stock Exchange(2025)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Original BioMedical focuses on developing new drug forms, dosages, and indications without introducing new active ingredients. Their platform can modify a drug’s half-life, enhance efficacy, and reduce side effects, enabling repurposing of existing drugs to shorten development time and revive near-failure compounds. They handle lab-scale synthesis, purification, method and dosage form development, and preclinical testing, while formal preclinical and clinical production is conducted at cGMP-certified manufacturing facilities.
